Apixaban and clarithromycin — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Increased apixaban exposure and bleeding risk
Clarithromycin can inhibit pathways involved in apixaban clearance, increasing bleeding risk. The interaction should be assessed before supply. In this scenario, the correct option is increased apixaban exposure and bleeding risk. The other options are plausible but do not address the key clinical, legal or safety issue as directly. This aligns with UK pharmacy practice guidance cited in the reference field.
Reference: BNF; Stockley's Drug Interactions